MILWAUKEE, Sept. 16, 2019 /PRNewswire/ -- Ademi &
O'Reilly, LLP is investigating Alder (Nasdaq: ALDR) for
possible breaches of fiduciary duty and other violations of the law
in connection with the sale of Alder to H. Lundbeck.
Click here to learn how to join the action:
http://ademilaw.com/case/alder-biopharmaceuticals or call
Guri Ademi toll-free at
866-264-3995. There is no cost or obligation to you.
Ademi & O'Reilly, LLP alleges Alder's financial outlook is
improving and yet shareholders will receive the equivalent of only
up to $20 per share for each share of
Alder common stock. H. Lundbeck is acquiring Alder at a
substantial discount. The merger agreement unreasonably
limits competing bids for Alder by prohibiting solicitation of
further bids, and imposing a termination penalty if Alder accepts a
superior bid. Alder insiders will receive millions of dollars as
part of change of control arrangements. We are investigating on the
conduct of Alder's board of directors, and whether they are (i)
fulfilling their fiduciary duties to all shareholders, and (ii)
obtaining a fair and reasonable price for Alder.
If you own common stock in Alder and wish to obtain additional
information, please contact Guri
Ademi either at gademi@ademilaw.com or toll-free:
866-264-3995, or http://ademilaw.com/case/alder-biopharmaceuticals.
We specialize in shareholder litigation involving buyouts,
mergers, and individual shareholder rights throughout the country.
For more information, please feel free to call us. Attorney
advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi & O'Reilly, LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original
content:http://www.prnewswire.com/news-releases/shareholder-alert-ademi--oreilly-llp-investigates-whether-alder-biopharmaceuticals-has-obtained-a-fair-price-in-its-sale-to-h-lundbeck-as-300918689.html
SOURCE Ademi & O'Reilly, LLP